培美曲塞联合顺铂治疗晚期乳腺癌的疗效观察(1)
 |
| 第1页 |
参见附件(2946KB，3页)。
[摘要] 目的：观察培美曲塞联合顺铂治疗晚期乳腺癌的临床疗效和不良反应。方法：培美曲塞500 mg/m2，第1 天；顺铂75 mg/m2，第1 天，21 d为1个周期。所有病例均接受至少2个周期的化疗。结果：30例患者入组均可评价疗效，CR为0，PR为20.0%(6/30)，SD为46.7%(14/30)，PD为33.3%(10/30)，有效率为20.0%(6/30)，临床获益率为46.7%(14/30)。中位随访期10个月，中位TTP 7个月，中位OS 8.5个月，1年生存率为63.3%。主要不良反应为骨髓毒性，有6例(20.0%，6/30)发生了Ⅲ～Ⅳ度白细胞减少；有4例(13.3%，4/30)发生了Ⅲ度血小板减少。结论：培美曲塞联合顺铂方案治疗蒽环类和紫杉类化疗失败的转移性乳腺癌有较好的疗效，患者耐受性好，值得临床进一步研究。
[关键词] 转移性乳腺癌 化疗 培美曲塞 顺铂
[中图分类号] R737.9[文献标识码]B [文章编号]1673-7210(2011)02(b)-054-03
Clinical experience of Pemetrexed combined with Cisplatin in treating patients with advanced metastatic breast cancer
FU Jing, SHI Shuzhen
(Dalian Tumor Hospital, Dalian 116031, China)
[Abstract] Objective: To observe the efficacy and toxicity of the combination of Pemetrexed and Cisplatin in the treatment of Anthracycline and Taxane-resistant advanced metastatic breast cancer (MBC) patients. Methods: Thirty patients with advanced MBC failed to previous chemotherapy with Anthracycline and Taxane were enrolled into the study. The patients received Pemetrexed 500 mg/m2 on days 1, and Cisplatin 75 mg/m2 on day 1, with 21 days as a cycle. Each patient received at least two cycles. Results: Of the thirty patients, 0 cases got complete response, 6 got partial response, 14 had stable disease，and 10 had progressive disease, with the overall response rate was 20.0%(6/30), the clinical benefit rate was 46.7%(14/30). With a median follow-up of 10 months. The median TTP was 7 months. The median OS was 8.5 months. The 1 year survival rate was 63.3%. The main toxic reactions were myelosuppression, leukopenia (incidence of 20.0% for gradeⅢ-Ⅳ) and thrombocytopenia (incidence of 13.3% for gradeⅢ). Conclusion: The combination of Pemetrexed and Cisplatin is active in the treatment of advanced MBC who have failed Anthracyclines and Taxanes with acceptable toxicity, and may be an effective salvage therapy.
[Key words] Metastatic breast cancer; Chemotherapy; Pemetrexed; Cisplatin.
乳腺癌是妇女常见的一种恶性肿瘤，目前占女性死因的第一位，术后复发转移的患者为数不少。有报道即使是Ⅰ期乳腺癌患者，最终有20%死于本病。化疗在乳腺癌的综合治疗模式中有着重要的作用，含蒽环类或紫杉类药物的化疗方案是目前治疗晚期乳腺癌较有效的一线方案，但临床上仍有20%～30%的患者产生耐药，对于一线治疗失败目前还没有标准的二线化疗方案。
培美曲塞是一种细胞毒药物 ......
您现在查看是摘要介绍页，详见PDF附件(2946KB，3页)。